R. F. Patientia

The Diarylquinoline TMC207 for Multidrug-Resistant Tuberculosis

Andreas H. Diacon, Alexander S. Pym, Martin P. Grobusch et al. · New England Journal of Medicine · 2009 · 839 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Randomized Pilot Trial of Eight Weeks of Bedaquiline (TMC207) Treatment for Multidrug-Resistant Tuberculosis: Long-Term Outcome, Tolerability, and Effect on Emergence of Drug Resistance

Andreas H. Diacon, Peter R. Donald, Alexander S. Pym et al. · Antimicrobial Agents and Chemotherapy · 2012 · 380 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +13

Early Bactericidal Activity and Pharmacokinetics of the Diarylquinoline TMC207 in Treatment of Pulmonary Tuberculosis

Roxana Rustomjee, Andreas H. Diacon, Jenny Allen et al. · Antimicrobial Agents and Chemotherapy · 2008 · 278 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +15

Early Bactericidal Activity of High-Dose Rifampin in Patients with Pulmonary Tuberculosis Evidenced by Positive Sputum Smears

Andreas H. Diacon, R. F. Patientia, Amour Venter et al. · Antimicrobial Agents and Chemotherapy · 2007 · 199 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +12

Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial

Florian von Groote-Bidlingmaier, R. F. Patientia, Epifanio Sánchez et al. · The Lancet Respiratory Medicine · 2019 · 163 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +10